Alyeska Investment Group
KPTI icon

Alyeska Investment Group’s Karyopharm Therapeutics KPTI Stock Holding History

Alyeska Investment Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,113
Closed -$862K – 564
2023
Q2 		$862K Hold
32,113
– – 0.01% 462
2023
Q1 		$1.87M Hold
32,113
– – 0.02% 357
2022
Q4 		$1.64M Buy
+32,113
New +$2.23M 0.02% 333
2019
Q2 		– Sell
-33,333
Closed -$2.92M – 484
2019
Q1 		$2.92M Buy
+33,333
New +$3.69M 0.04% 261
2014
Q1 		– Sell
-5,000
Closed -$1.72M – 362
2013
Q4 		$1.72M Buy
+5,000
New +$1.38M 0.07% 241

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Alyeska Investment Group's KPTI Position: Q3 2023 in Review

Alyeska Investment Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 32,113 shares — an estimated $862K sold.

Alyeska Investment Group first reported a position in KPTI in Q4 2013 and held it in 5 quarters. The position peaked at $2.92M in Q1 2019. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

  • Alyeska Investment Group reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 32,113 Karyopharm Therapeutics shares in Q3 2023, an estimated $862K.
  • Alyeska Investment Group first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 5 quarters.
  • Alyeska Investment Group's Karyopharm Therapeutics position peaked at $2.92M in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Alyeska Investment Group's 13F filing for Q3 2023, filed 14 Nov 2023.